Lobbying Information
Subject Matters
- Aboriginal Affairs
- Budget
- Consumer Issues
- Environment
- Government Procurement
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Trade
- Regional Development
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
Legislative Proposal, Bill or Resolution, Policies or Program
- International Trade policy initiatives related to implementing / strengthening the Canada-Europe Trade Agreement (CETA), including recognition of patent term restoration within Canada's intellectual property protection regime
Legislative Proposal, Bill or Resolution, Regulation
- Food and Drugs Act & regulations as they relate to export restrictions and cross border trade of biopharmaceuticals.
Policies or Program
- Canadian Institutes of Health (CIHR) initiatives, such as the Drug Safety and Effectiveness Network (DSEN), and various research programs, particularly as they relate to public/private research and development partnerships
- Environment Canada and/or Food and Drugs Act regulations as they relate to the safe and environmentally responsible disposal of biopharmaceutical compounds.
- Existing or proposed policies and programs related to ensuring availability and access to effective cancer treatments for Canadian patients.
- Existing or proposed policies and programs related to improving access to effective treatments for common mental health and addiction disorders for Canadian patients.
- Federal Health Partnership with respect to the co-ordination of federal health benefit plan policies and programs.
- Federal policies related to, and interactions with, the Canadian Agency for Drugs and Technologies in Health (CADTH) particularly pertaining to its Common Drug Review (CDR), Health Technology Assessment (HTA), and the Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) units.
- Health Canada support for, or partnerships with, the Canadian Network for Mood and Anxiety Treatments (CANMAT)
- Health Canada's "Notice of Compliance with Conditions (NOC/c)" policy with regards to therapeutic products
- Health benefits programs of Citizenship and Immigration Canada, Correctional Services of Canada, Health Canada (NIHB), the Department of National Defence, the Royal Canadian Mounted Police, and Veterans Affairs Canada with respect to decisions and policies which impact the reimbursement of biopharmaceutical therapeutic products for plan beneficiaries.
- International Trade Canada's "Invest in Canada" policies and programs with respect to investment, business development and innovation in the life sciences industry sector.
- Mobilizing Science and Technology to Canada's Advantage, the federal science and technology strategy, with respect to the health and related life sciences and technologies priority area
- Modernization of Health Canada's Progressive Licensing framework as it relates to the review and approval of biopharmaceutical products
- National Pharmaceutical Strategy (NPS) as it relates to the federal government's involvement in the federal/provincial/territorial governments' access to medicines framework
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program as it relates to investment in biopharmaceutical and related health technology innovation.
Policies or Program, Regulation
- Data exclusivity as it relates to the use of Natural Health Products in biopharmaceutical preparations.
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
Regulation
- Food and Drug Regulations as it relates to data protection (Section C.08.004) and the regulation and protection of biopharmaceutical products
- Patent Act with respect to Patented Medecines (Notice of Compliance (NOC)) Regulations
- Patented Medicines Prices Review Board (PMPRB) Regulations as they relate to reporting requirements and pricing guidelines
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
-
As part of Industry associations & delegations
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Canada Border Services Agency (CBSA)
-
Canada Economic Development for Quebec Regions
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Development Agency (CIDA)
-
Citizenship and Immigration Canada
-
Competition Bureau Canada (COBU)
-
Correctional Service of Canada (CSC)
-
Environment Canada
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Justice Canada (JC)
-
NAFTA Secretariat
-
National Defence (DND)
-
Patented Medicine Prices Review Board (PMPRB)
-
Public Health Agency of Canada (PHAC)
-
Royal Canadian Mounted Police (RCMP)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
Lundbeck Canada develops, manufactures and/or sells innovative biopharmaceutical products for the treatment of disorders originating in the central nervous system (CNS) and for the treatment of cancer.
Responsible officer name and position during the period of this registration
Patrick Cashman,
President & General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
1000, rue de la Gauchetiere ouest
Suite 500
Montreal, QC H3B 4W5
Canada
Telephone number:
514-844-8515
Fax number:
514-844-5495
Parent Company Information
- H. Lundbeck a/s
-
Ottilavej 9
Copenhagen Valby DK-2500
Denmark
Subsidiary Beneficiary Information
Lundbeck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Patrick Cashman,
President & General Manager |
No public offices held
- Marcel Chenard,
Senior Director, Commercial Development & Product Readiness |
No public offices held
- Marie Gagne,
Vice-President, Scientific Affairs |
No public offices held
- Dominique Gilbert,
Senior Director, Market Access & Health Outcomes |
No public offices held
- Steven Lamoureux,
Senior Director, Regulatory Affairs & GMP Compliance |
No public offices held
- Sylvie Pilon,
Senior Director, Oncology Business Unit |
No public offices held
- Jean Proulx,
Senior Director, Scientific Affairs |
No public offices held
- Marie-France Vincent,
Senior Director, Finance |
Public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Fakher Aissa,
Manager, Market Access - Oncology |
No public offices held
- Michael Leo,
Manager, Market Access |
No public offices held
